Printer Friendly

CLSI Publishes New Antimicrobial Susceptibility Testing Standard.

WAYNE, Pa. -- CLSI has recently published the annual update of the well-known antimicrobial susceptibility testing standard, Performance Standards for Antimicrobial Susceptibility Testing; Seventeenth Informational Supplement (M100-S17), which provides updates of the latest recommendations for detecting emerging resistance of aerobic bacteria--arranged in tabular format. The "breakpoints" included in the supplement are defined as specific values on the basis of which bacteria can be assigned to the clinical categories of susceptible, intermediate, or resistant. This essential information assists clinicians with drug selection, interpretation, and quality control using the procedures standardized in CLSI documents Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard--Ninth Edition (M2-A9); and Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard--Seventh Edition (M7-A7).

Janet F. Hindler, MCLS, MT(ASCP), Senior Specialist, Clinical Microbiology, UCLA Medical Center, explains, "For over three decades, NCCLS and now CLSI consensus standards have been the primary resources for antimicrobial susceptibility testing in the clinical laboratory. The annual updates provide the most current recommendations to ensure accurate detection and reporting of emerging resistance."

This edition of the supplement includes updated tables from CLSI's disk (M2-A9) susceptibility and MIC (M7-A7) testing standards. In addition, the document provides three pages of adhesive index tabs, which can be inserted for quick access to each table.

Updates include:

* new disk diffusion and MIC interpretive criteria for colistin and polymyxin B;

* new antimicrobial agents and QC ranges;

* preparation of stock solutions for antimicrobial agents provided with activity expressed as units;

* added information on the development of resistance and testing of repeat isolates;

* modified recommendations for testing and reporting designated clusters of agents with similar interpretive results and clinical efficacy;

* recommendations for reporting critical results; and

* suggestions for verification and confirmation of susceptibility testing results for Neisseria meningitidis.

For additional information on CLSI or for further information regarding this release, visit our website at http://www.clsi.org or call +610.688.0100.

CLSI is a global, nonprofit, membership-based organization dedicated to developing standards and guidelines for the healthcare and medical testing community. CLSI's unique consensus process facilitates the creation of standards and guidelines that are reliable, practical, and achievable for an effective quality system.
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jan 3, 2007
Words:358
Previous Article:CLSI Publishes New Guideline for Managing and Validating Laboratory Information Systems.
Next Article:Harrah's Opens Employee Health and Wellness Center.
Topics:


Related Articles
Rifampin-resistant meningococcal disease.
Isolate removal methods and methicillin-resistant Staphylococcus aureus surveillance.
Contrasting pediatric and adult methicillin-resistant Staphylococcus aureus isolates.
VIM-1 metallo-[beta]-lactamase in Acinetobacter baumannii.
Carbapenem resistance in Klebsiella pneumoniae not detected by automated susceptibility testing.
Serotype competence and penicillin resistance in Streptococcus pneumoniae.
Catheter-related bacteremia and multidrug-resistant Acinetobacter Iwoffii.
Intermediate vancomycin susceptibility in a community-associated MRSA clone.
Drug-resistant nontyphoidal Salmonella bacteremia, Thailand [1].
International spread of multidrug-resistant Salmonella Schwarzengrund in food products.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters